Drugs / CpG55.2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03945825 | Jun 2019 → Sep 2020 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-04-22 | Vaxine Pty Ltd | Results Phase 2 trial results vaxine.net ↗
Vaxine is pleased to see its latest Covid-19 vaccine Phase 2 trial results complete peer review and be published in the journal “Clinical Microbiology and Infection”, the official journal of the European Society of Clinical Microbiology and Infectious Diseases. |
| 2022-04-01 | Vaxine Pty Ltd | Regulatory TGA grants Provisional Determination to Vaxine for its COVID-19 Recombinant Protein Vaccine vaxine.net ↗
The Therapeutic Goods Administration (TGA), part of the Department of Health, has granted provisional determination to Vaxine Pty Ltd in relation to its COVID-19 vaccine: Recombinant CoV-2-S-ΔTM protein with Advax-CpG55.2 (active ingredient name and tradename to be confirmed). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-04-22 | Vaxine Pty Ltd | Phase 2 trial results vaxine.net ↗ |
| 2022-04-01 | Vaxine Pty Ltd | TGA grants Provisional Determination to Vaxine for its COVID-19 Recombinant Protein Vaccine vaxine.net ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CpG55.2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03945825 ↗ |
| Route | Intramuscular | “0.5 mL of 2018/2019 Fluzone QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection” NCT03945825 ↗ |